<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2326-2-4.anc" start="24253" end="24258" sStart="-1" offset="0" sid="null" wn="2" wnkey="write%2:32:00::" text="Author 2 (KFH) contributed to the study design, did the literature search and data abstraction, conducted the analyses, interpreted results and &lt;b&gt;wrote&lt;/b&gt; the manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2326-2-4.anc" start="24373" end="24380" sStart="null" offset="0" sid="null" wn="2" wnkey="write%2:32:00::" text="Author 3 (TCG) did the literature search and data abstraction, and contributed to &lt;b&gt;writing&lt;/b&gt; the manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2326-2-4.anc" start="9565" end="9572" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Analyses were carried out with SAS version 6.12 for &lt;b&gt;Windows&lt;/b&gt;." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="134" end="140" sStart="null" offset="91" sid="r11.severe.j.0071" wn="1" wnkey="severe%5:00:00:intense:00" text="The thalassemias are a group of inherited disorders of hemoglobin [ 1 ] , the most severe form of which is beta thalassemia major." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="134" end="140" sStart="null" offset="91" sid="r11.severe.j.0071" wn="1" wnkey="severe%5:00:00:intense:00" text="The thalassemias are a group of inherited disorders of hemoglobin [ 1 ] , the most severe form of which is beta thalassemia major." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="14488" end="14499" sStart="null" offset="184" sid="r11.recommend.v.0452" wn="2147483645" wnkey="null" text="The doses of deferiprone - even in the optimal dose group - are relatively low, compared to the desferrioxamine doses, which in most studies are well above the recommended 40 mg/kg/day." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="589" end="595" sStart="null" offset="409" sid="r9.normal.j.0167" wn="3" wnkey="normal%3:00:03::" text="Improvements in the management of patients with thalassemia major in the past four decades have resulted in &quot;one of the most dramatic alterations in morbidity and mortality associated with a genetic disease&quot; [ 2 ] . Regular red blood cell transfusions extend survival, eliminate complications of anemia, inhibit bone marrow hyperactivity, and support normal growth and development in patients with thalassemia major [ 3 ] . Unfortunately, regular transfusions also lead to the accumulation of tissue iron, loading the body's organs to the point of dysfunction and finally death in the second or third decade of life if left untreated [ 4 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="9328" end="9333" sStart="null" offset="199" sid="r9.level.n.0788" wn="3" wnkey="level%1:26:00::" text="Finally, additional analyses were conducted to explore the impact on the odds of improvement of including the few studies that provided summary information at the study level only." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="23876" end="23885" sStart="null" offset="110" sid="r1.influence.n.0100" wn="1" wnkey="influence%1:07:00::" text="This work was supported in part by a grant from Novartis Pharma AG Basel, but was carried out without influence from its sponsor." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="23876" end="23885" sStart="null" offset="110" sid="r1.influence.n.0100" wn="4" wnkey="influence%1:19:00::" text="This work was supported in part by a grant from Novartis Pharma AG Basel, but was carried out without influence from its sponsor." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="23876" end="23885" sStart="null" offset="110" sid="r1.influence.n.0100" wn="4" wnkey="influence%1:19:00::" text="This work was supported in part by a grant from Novartis Pharma AG Basel, but was carried out without influence from its sponsor." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="4315" end="4319" sStart="null" offset="275" sid="r9.full.j.0165" wn="2" wnkey="full%5:00:01:whole:00" text="Indeed, to our knowledge, only one randomized controlled trial comparing desferrioxamine and deferiprone has been conducted and results for that study are incomplete as the trial was terminated prematurely and has not been reported in full [ 9 10 11 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="4498" end="4509" sStart="null" offset="144" sid="r11.combination.n.0709" wn="1" wnkey="combination%1:14:00::" text="The National Library of Medicine's computerized bibliographic database (Medline 1966 to December 1999) was searched using a combination of the following keywords: thalassemia, serum ferritin, urinary iron excretion, hepatic iron, liver, chelation therapy, iron chelation, iron chelating agents, desferal, desferrioxamine, deferoxamine, L1 oral chelate, deferiprone and 1,2-dimethyl-3-hydroxypyrid-4-one." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="22777" end="22788" sStart="null" offset="523" sid="r11.combination.n.0821" wn="1" wnkey="combination%1:14:00::" text="A case-control study in 15 patients treated with deferiprone (cases) and 30 patients treated with desferrioxamine (controls) matched for age and serum ferritin levels, demonstrated that deferiprone appears to be more effective than desferrioxamine in removal of myocardial iron despite significantly higher HIC in the deferiprone group [ 5 ] . Although a larger prospective trial is needed to confirm the results, these findings would suggest that a combination of both drugs may be most beneficial in order to reduce both hepatic and myocardial concentrations of iron." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2326-2-4.anc" start="16513" end="16521" sStart="null" offset="85" sid="r11.benefit.n.0180" wn="2" wnkey="benefit%1:07:00::" text="Several systematic, qualitative reviews [ 2 8 23 24 ] highlight the clinical benefits of desferrioxamine treatment and, with respect to iron loading, acknowledge its ability to maintain harmless hepatic iron levels in properly chelated patients." />
  </sentences>
</list>